利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

125 条记录 (耗时 0.026 秒)

    SOLID PHARMACEUTICAL COMPOSITION
    41.
    发明公开
    SOLID PHARMACEUTICAL COMPOSITION 审中-公开
    FESTE PHARMAZEUTISCHE ZUSAMMENSETZUNG

    公开(公告)号：EP2990039A4

    公开(公告)日：2017-02-22

    申请号：EP14789034

    申请日：2014-04-24

    申请人： KYORIN SEIYAKU KK

    发明人： UCHIDA HIROSHI ,  HANADA MASATAKA ,  MIYAZAKI YOSHIKAZU

    IPC分类号： A61K31/4709 ,  A61K9/20 ,  A61K9/28 ,  A61P31/04

    CPC分类号： A61K9/2054 ,  A61K9/2013 ,  A61K9/2853 ,  A61K9/2866 ,  A61K31/4709

    摘要： [Problem] To provide a novel pharmaceutical composition which contains a medically active component and which can suppress delays in the release of said component due to gelling. [Solution] This solid pharmaceucical composition contains a compound represented by general formula (1), or a salt thereof, a cellulosic excipient, and a salting-out agent.

    摘要翻译： [问题]提供含有医药活性成分并且可以抑制由于胶凝而导致的所述成分的释放延迟的新型药物组合物。 [溶液]该固体药物组合物含有通式（1）表示的化合物或其盐，纤维素赋形剂和盐析剂。

    4-(3-BENZYLOXYPHENYLTHIO)-2-CHLORO-1-(3-NITROPROPYL)BENZENE CRYSTAL
    43.
    发明公开
    4-(3-BENZYLOXYPHENYLTHIO)-2-CHLORO-1-(3-NITROPROPYL)BENZENE CRYSTAL 有权
    4-（3-苄氧基苯硫基）-2- CHLOR-1-（3-硝基丙基）BENZOLKRISTALL

    公开(公告)号：EP2840079A4

    公开(公告)日：2015-11-18

    申请号：EP13778567

    申请日：2013-04-17

    申请人： KYORIN SEIYAKU KK

    发明人： TSUBUKI TAKESHI ,  SATO HIROYA

    IPC分类号： C07C323/20 ,  C07C319/28

    CPC分类号： C07C323/20 ,  C07B2200/13 ,  C07C319/28

    摘要： 4-(3-benzyloxyphenylthio)-2-chloro-1-(3-nitropropyl)benzene (compound 1) is used as an intermediate for producing a 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1-,3-propanediol hydrochloride which has excellent immunosuppressive activity. This compound 1 is traditionally obtained only as an oil and thus handling and refining were difficult. [Solution] A crystal of the compound 1 is obtained. A method of crystallizing the same is also established. Furthermore, a simple refining method is also found which comprises stirring in suspension the crystal in a solvent. Since the compound 1 can be obtained as a crystal, it is easier to handle and long term storage is possible.

    METHOD FOR PRODUCTION OF SUSTAINED RELEASE TABLET
    46.
    发明公开
    METHOD FOR PRODUCTION OF SUSTAINED RELEASE TABLET 审中-公开
    方法用于生产具有持续释放的片剂

    公开(公告)号：EP2090298A4

    公开(公告)日：2014-02-26

    申请号：EP07831649

    申请日：2007-11-12

    申请人： KYORIN SEIYAKU KK

    发明人： NAKASHIMA KATASHI ,  KAZAMA KAZUO

    IPC分类号： A61K9/20 ,  A61J3/06 ,  A61J3/10 ,  A61K9/28 ,  A61K47/38

    CPC分类号： A61J3/10 ,  A61K9/2077

    摘要： Herein provided is a method for easily preparing a sustained release tablet which contains an orally administrable medicinal component, while maintaining the uniformity of the content of the medicinal component. The method comprises mixing (1) a granulated product A obtained by granulating an excipient and an enteric coating agent while spraying thereon with a solution or a suspension containing an orally administrable medicinal component, with (2) a composition B containing a hydrogel-forming substance; and then compressing the resulting mixture into a tablet.

    AQUEOUS LIQUID PREPARATION HAVING IMPROVED INTRAOCULAR GATIFLOXACIN PENETRATION
    49.
    发明公开
    AQUEOUS LIQUID PREPARATION HAVING IMPROVED INTRAOCULAR GATIFLOXACIN PENETRATION 审中-公开
    具有改进的加替沙星眼内穿透水性液体制剂

    公开(公告)号：EP2078526A4

    公开(公告)日：2011-08-10

    申请号：EP07829584

    申请日：2007-10-11

    申请人： KYORIN SEIYAKU KK ,  SENJU PHARMA CO

    发明人： SAWA SHIROU

    IPC分类号： A61K31/496 ,  A61K9/08 ,  A61K47/02 ,  A61K47/36 ,  A61P27/02 ,  A61P31/04

    CPC分类号： A61K31/496 ,  A61K9/0048 ,  A61K47/36

    摘要： An object is to provide an ophthalmic aqueous preparation excellent in the retention of gatifloxacin in a tear fluid and the preparation of gatifloxacin into an aqueous humor and a conjunctiva. Another object is to prevent the formation of any precipitate and the reduction in viscosity in the aqueous liquid preparation. An aqueous liquid preparation comprising gatifloxacin, a pharmacologically acceptable salt thereof or a hydrate of gatifloxacin or the salt and at least 0.15 w/v% of xanthan gum enables to improve the retention and penetration of gatifloxacin. When at least 0.2 w/v% of sodium chloride is added to the aqueous liquid preparation, the formation of any precipitate and the reduction in viscosity in the aqueous liquid preparation can be prevented.